title: A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.
abstract: A mutated cyclin-dependent kinase 4 (CDK4) was identified as a tumor-specific antigen recognized by HLA-A2. 1-restricted autologous cytolytic T lymphocytes (CTLs) in a human melanoma. The mutated CDK4 allele was present in autologous cultured melanoma cells and metastasis tissue, but not in the patient's lymphocytes. The mutation, an arginine-to-cysteine exchange at residue 24, was part of the CDK4 peptide recognized by CTLs and prevented binding of the CDK4 inhibitor p16INK4a, but not of p21 or of p27KIP1. The same mutation was found in one additional melanoma among 28 melanomas analyzed. These results suggest that mutation of CDK4 can create a tumor-specific antigen and can disrupt the cell-cycle regulation exerted by the tumor suppressor p16INK4a.
authors.affiliation: Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität, Mainz, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Wölfel
authors.forename: M
authors.initials: M
authors.lastname: Hauer
authors.forename: J
authors.initials: J
authors.lastname: Schneider
authors.forename: M
authors.initials: M
authors.lastname: Serrano
authors.forename: C
authors.initials: C
authors.lastname: Wölfel
authors.forename: E
authors.initials: E
authors.lastname: Klehmann-Hieb
authors.forename: E
authors.initials: E
authors.lastname: De Plaen
authors.forename: T
authors.initials: T
authors.lastname: Hankeln
authors.forename: K H
authors.initials: KH
authors.lastname: Meyer zum Büschenfelde
authors.forename: D
authors.initials: D
authors.lastname: Beach
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D001483:Base Sequence; D002352:Carrier Proteins / Q000378:metabolism / Q000494:pharmacology*; D018797:Cell Cycle Proteins; D002460:Cell Line; D003001:Cloning, Molecular; D051358:Cyclin-Dependent Kinase 4; D050762:Cyclin-Dependent Kinase Inhibitor p15; D019941:Cyclin-Dependent Kinase Inhibitor p16; D050759:Cyclin-Dependent Kinase Inhibitor p21; D050760:Cyclin-Dependent Kinase Inhibitor p27; D018844:Cyclin-Dependent Kinases; D016213:Cyclins / Q000378:metabolism / Q000494:pharmacology; D015789:HLA-A2 Antigen / Q000276:immunology; D006801:Humans; D008545:Melanoma / Q000201:enzymology / Q000276:immunology*; D008869:Microtubule-Associated Proteins / Q000378:metabolism / Q000494:pharmacology; D008969:Molecular Sequence Data; D017354:Point Mutation; D016133:Polymerase Chain Reaction; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D011518:Proto-Oncogene Proteins; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014162:Transfection; D014407:Tumor Cells, Cultured; D025521:Tumor Suppressor Proteins
chemical_list: C493956:CDKN1A protein, human; C493966:CDKN2B protein, human; D002352:Carrier Proteins; D018797:Cell Cycle Proteins; D050762:Cyclin-Dependent Kinase Inhibitor p15; D019941:Cyclin-Dependent Kinase Inhibitor p16; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D015789:HLA-A2 Antigen; D008869:Microtubule-Associated Proteins; D011518:Proto-Oncogene Proteins; D025521:Tumor Suppressor Proteins; D050760:Cyclin-Dependent Kinase Inhibitor p27; D017346:Protein Serine-Threonine Kinases; C495900:CDK4 protein, human; D051358:Cyclin-Dependent Kinase 4; D018844:Cyclin-Dependent Kinases